BRPI0411451A - formas de dosagens orais de memantina - Google Patents

formas de dosagens orais de memantina

Info

Publication number
BRPI0411451A
BRPI0411451A BRPI0411451-5A BRPI0411451A BRPI0411451A BR PI0411451 A BRPI0411451 A BR PI0411451A BR PI0411451 A BRPI0411451 A BR PI0411451A BR PI0411451 A BRPI0411451 A BR PI0411451A
Authority
BR
Brazil
Prior art keywords
memantine
dosage form
oral dosage
dosage forms
patient
Prior art date
Application number
BRPI0411451-5A
Other languages
English (en)
Inventor
Bruce A Firestone
John J Vander Zanden
Janet K Cheetham
Richard Kurjan
Teresa H Kuan
Chin-Ming Chang
J Abraham M Espiritu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0411451A publication Critical patent/BRPI0411451A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMAS DE DOSAGENS ORAIS DE MEMANTINA". A presente invenção refere-se a uma forma de dosagem oral contendo entre 1 mg e 100 mg de memantina, em que a forma de dosagem referida não contém 10 mg de memantina ou 20 mg de memantina, e em que a forma de dosagem referida não é preparada pelo paciente ou por uma pessoa que esteja administrando o fármaco ao paciente que divide a forma de dosagem contendo uma dose maior de memantina. Outro aspecto desta invenção refere-se a produtos farmacêuticos compreendendo as formas de dosagens referidas e métodos para administrar memantina e tratar doença com a forma de dosagem referida.
BRPI0411451-5A 2003-06-16 2004-06-10 formas de dosagens orais de memantina BRPI0411451A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47897903P 2003-06-16 2003-06-16
PCT/US2004/018506 WO2004112768A1 (en) 2003-06-16 2004-06-10 Memantine oral dosage forms

Publications (1)

Publication Number Publication Date
BRPI0411451A true BRPI0411451A (pt) 2006-07-18

Family

ID=33539133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411451-5A BRPI0411451A (pt) 2003-06-16 2004-06-10 formas de dosagens orais de memantina

Country Status (16)

Country Link
US (2) US20040254251A1 (pt)
EP (1) EP1631273A1 (pt)
JP (1) JP2006527774A (pt)
KR (1) KR20060033727A (pt)
CN (1) CN1805737A (pt)
AU (1) AU2004249151A1 (pt)
BR (1) BRPI0411451A (pt)
CA (1) CA2529535A1 (pt)
IL (1) IL172233A0 (pt)
MX (1) MXPA05012810A (pt)
NO (1) NO20055880L (pt)
PL (1) PL378902A1 (pt)
RU (1) RU2006101225A (pt)
TW (1) TW200524639A (pt)
WO (1) WO2004112768A1 (pt)
ZA (1) ZA200509379B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
FR2855344A1 (fr) * 2003-05-22 2004-11-26 France Telecom Systeme de gestion de contexte pour un reseau comportant un ensemble heterogene de terminaux
JP5025468B2 (ja) * 2004-06-17 2012-09-12 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン メマンチン又はネラメキサンの直接圧縮によって製造された、飲用に適した即効型錠剤
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CA2588295C (en) * 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
AU2007215005A1 (en) * 2006-02-10 2007-08-23 Janssen Pharmaceutica N.V. Novel tricyclic dihydropyrazines as potassium channel openers
JP4981036B2 (ja) * 2006-04-20 2012-07-18 伊藤ハム株式会社 コンフォメーション病医薬組成物
WO2008005036A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009084017A2 (en) 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009091932A2 (en) * 2008-01-18 2009-07-23 Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
BR112014026292B1 (pt) * 2012-04-24 2022-09-27 Daiichi Sankyo Company, Limited Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR20190076711A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods

Also Published As

Publication number Publication date
MXPA05012810A (es) 2006-02-13
PL378902A1 (pl) 2006-05-29
TW200524639A (en) 2005-08-01
RU2006101225A (ru) 2006-06-10
CN1805737A (zh) 2006-07-19
WO2004112768A1 (en) 2004-12-29
IL172233A0 (en) 2006-04-10
EP1631273A1 (en) 2006-03-08
US20060251717A1 (en) 2006-11-09
JP2006527774A (ja) 2006-12-07
US20040254251A1 (en) 2004-12-16
CA2529535A1 (en) 2004-12-29
KR20060033727A (ko) 2006-04-19
NO20055880L (no) 2005-12-28
ZA200509379B (en) 2006-11-29
AU2004249151A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
BRPI0411451A (pt) formas de dosagens orais de memantina
Mercadante et al. Pharmacological management of cancer pain in the elderly
CY1116041T1 (el) Μεσα και μεθοδοι για τη θεραπευτικη αγωγη νεοπλασματικων νοσων
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
BR0316906A (pt) administração do capsaicinoides
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0511296A (pt) sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
BRPI0313424B8 (pt) forma de dosagem e processo para a preparação de uma forma de dosagem
HRP20110035T1 (hr) Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0115162A (pt) Tratamentos antitumorais eficazes
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
BRPI0411079A (pt) composições farmacêuticas compreendendo atorvastatina, fabricadas sem granulação
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2008127882A (ru) Лечение пищевода барретта
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.